A study on the protective role of doxycycline upon dopaminergic neuron of LPS-PD rat model rat.
To investigate the protective role of doxycycline upon the dopaminergic neuron of the lipopolysaccharide-Parkinson disease (LPS-PD) model rat and its mechanism. Animals were randomly divided into three groups: normal control group, LPS group and doxycycline intervention. Group; establishing The PD model was created by injecting LPS stereo-tactically into the substantia nigra; observing the changes in the dopaminergic neurons and the major histocompatibility complex II (MHC II) positive microglia before and after the intervention of doxycycline with immunohistochemical staining. Using the HPLC-ED (high performance liquid chromatography-electrochemical detector) to test the changes in the striatal dopamine (DA), and DOPAC (dihydroxy phenyl acetic acid) content; adopting Western blotting was adopted to test the expression of the substantia nigra microglia MHC II (major histocompatibility complex II) protein. After the intervention of doxycycline, in the LPS group, the surviving dopamine neurons in the substantia nigra rose from 38% ± 5% to 79% ± 4% (p < 0.01); striatal DA and DOPAC content of the LPS group increased from 4.89 ± 0.27 and 0.70 ± 0.07 to 7.00 ± 0.34 and 1.10 ± o. 10 respectively (p < 0.01). The average number of rotation induced intraperitoneal injection of apomorphine of the animals in the LPS group reduced from (208 ± 14); time/30 min to (80 ± 12) times/30 min (p < 0.01); while the number of the MHC II positive cells in the substantia nigra pars compacta in the LPS group reduced from 835 ± 82 to 354 ± 59 (p < 0.01); Western blotting of the MHC II protein expression showed a significant reduction. Doxycycline can inhibit degeneration of LPS-induced dopaminergic neurons. Its neuroprotective function is achieved by downregulating the microglia MHC II expression.